Thomas Englese
CIK: 0001825799
Transaction Breakdown
Open Market Buys (P)0
High conviction signal
Open Market Sales (S)0
Position reduction
Option Exercises (M)0
Derivative conversions
Awards (A)0
Compensation grants
Other (G, F, J, C, D, …)0
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
TNXP
Tonix Pharmaceuticals Holding Corp.
Officer
Discretionary Trading P&L
Holdings
Transaction History (0 total)
1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024.
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| 1 Form 3 filing on record — initial statements of ownership, which report holdings, not trades. No Form 4 or Form 5 transactions since Sep 2024. | ||||||
0-0 of 0 transactions
About Englese Thomas
Englese Thomas (SEC CIK 0001825799) files insider reports with the SEC as Chief Commercial Officer of Tonix Pharmaceuticals Holding Corp. (TNXP).
Signal8 holds 1 ownership filing by Englese Thomas, a Form 3, filed on Sep 8, 2026. A Form 3 is an initial statement of ownership: it reports holdings, not trades, so no Form 4 or Form 5 transactions are on record since Sep 2024.
The business address on Englese Thomas's filings is in BERKELEY HEIGHTS, NJ.
Other insiders filing for Tonix Pharmaceuticals Holding Corp. (TNXP)
- BAGGER RICHARD H, Director
- SAENGER BRADLEY, Chief Financial Officer
- Taylor Carolyn E., Director
- Stillwell Richard Newcomb, Director
- LEDERMAN SETH, Chief Executive Officer
- OLUKOTUN ADEOYE Y, Director